Mathieu Le Gars - Concepedia

Author

Mathieu Le Gars

Also Known As

Borducchi, Erica N., Gars, Mathieu Le, Le Gars, Mathieu, Mathieu Le Gars, Mathieu Legars, Mathieu Le Gars, Mathieu le Gars, Nga Le

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Janssen (Netherlands)Janssen (Belgium)Beth Israel Deaconess Medical Center South African Medical Research Council Ragon Institute of MGH, MIT and Harvard

About

Mathieu Le Gars is an author at Janssen (Netherlands) specializing in immunology, medicine, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	484
2	Allergy	1	1	19
3	Cell Biology	1	1	19
4	Clinical Immunology	1	1	32
5	Epidemiology	1	1	28

Mathieu Le Gars

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Jerald Sadoff, Glenda Gray, An Vandebosch, New England Journal of Medicine	2021	2.5K
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, New England Journal of Medicine	2021	1.2K
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans Galit Alter, Jingyou Yu, Jinyan Liu, Nature	2021	342
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 Kathryn E. Stephenson, Mathieu Le Gars, Jerald Sadoff, JAMA	2021	313
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S Jerald Sadoff, Glenda Gray, An Vandebosch, New England Journal of Medicine	2022	246
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Viral DiagnosticsImmunologyImmunodominancePlacebo-controlled TrialPhase 1/2A	2020	141
Neutrophil Elastase Degrades Cystic Fibrosis Transmembrane Conductance Regulator via Calpains and Disables Channel Function <i>In Vitro</i> and <i>In Vivo</i> Mathieu Le Gars, Delphyne Descamps, Delphine Roussel, American Journal of Respiratory and Critical Care Medicine	2012	102
Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing Delphyne Descamps, Mathieu Le Gars, Viviane Balloy, Proceedings of the National Academy of Sciences	2012	97
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial Youyi Fong, Adrian B. McDermott, David Benkeser, Nature Microbiology VaccinationVaccine DevelopmentImmunologyVaccine EfficacyMedicine	2022	89
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial Karin Hardt, An Vandebosch, Jerald Sadoff, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing	2022	84

Page 1